No, a new study doesn t show the J&J vaccine is ineffective against delta
A new study claims that the antibodies created through the Johnson & Johnson COVID-19 vaccine may not be as strong as those created by the Pfizer and Moderna vaccines. But experts say the study is no cause to rush to conclusions about the vaccine.
and last updated 2021-07-21 08:55:52-04
SAN DIEGO (KGTV) A new study released Tuesday suggests the COVID-19 vaccine made by Johnson & Johnson produces significantly weaker antibody defenses to the delta variant compared to the original virus.
However, several experts told ABC 10News the results are far from proof that the one-dose vaccine is ineffective against the variant in the real world.
No, a new study doesn t show the J&J vaccine is ineffective against the delta variant
newschannel5.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newschannel5.com Daily Mail and Mail on Sunday newspapers.
Can we stretch existing Covid vaccines to inoculate more people?
statnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from statnews.com Daily Mail and Mail on Sunday newspapers.
Print
Japanese pharma giant Kyowa Kirin is set to receive $400 million in a deal that wouldn’t have happened without the company’s San Diego lab.
The company recently announced a partnership with Amgen to develop a drug against eczema, a skin condition that can leave painful and itchy rashes across your hands, feet and behind your knees, among other places. Those rashes break out when irritants and allergens pass through the outermost layer of skin, triggering inflammation.
Kyowa Kirin’s experimental treatment, developed by scientists at its La Jolla lab, targets immune cells responsible for these inflammatory signals. The drug uses an antibody, a Y-shaped protein, to target T cells, immune cells that normally play a key role in fighting off microbes but can also trigger friendly fire against the body’s own tissues. The small arms of that Y latch onto the surface of activated T cells, while scientists modified the other end to efficiently trigger other immune cells to kill